drugset / Trial / NCT03353857

Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam

NCT03353857

Phase 1 Completed 68 enrolled Bayer
RandomizedParallel-groupOpen-labelOther

Summary

Quantify the effect of a probe CYP3A4 inducer (Rifampicin) on the pharmacokinetics of levonorgestrel, norethindrone, desogestrel, dienogest, drospirenone,estradiol and midazolam

Timeline

Start
2017-11-29
Primary completion
2018-07-04
Completion
2019-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Desogestrel Small molecule 0.075 mg
Subject Dienogest Small molecule 2 mg
Subject Levonorgestrel Small molecule 0.03 mg
Subject Midazolam Small molecule 1 mg Oral
Subject Norethindrone Unknown 0.35 mg
Subject Rifampin Small molecule 10 mg
Subject Rifampin Small molecule 600 mg
Subject drospirenone Unknown 3 mg
Subject ethinyl estradiol Small molecule 0.03 mg

Indications

No indication recorded.